<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJCM</journal-id><journal-title-group><journal-title>International Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2158-284X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijcm.2015.66054</article-id><article-id pub-id-type="publisher-id">IJCM-57461</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Pituitary Function in the Acute Phase of Traumatic Brain Injury and Subarachnoid Hemorrhage
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>nna</surname><given-names>Tölli</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jörgen</surname><given-names>Borg</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bo-Michael</surname><given-names>Bellander</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Charlotte</surname><given-names>Höybye</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden</addr-line></aff><aff id="aff3"><addr-line>Department of Molecular Medicine and Surgery, Karolinska Institutet and Department of Endocrinology, 
Metabolism and Diabetology, Karolinska University Hospital, Stockholm, Sweden</addr-line></aff><aff id="aff2"><addr-line>Department of Clinical Neuroscience, Section for Neurosurgery, Karolinska Institutet, Stockholm, Sweden</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>anna.tolli@ki.se(NT)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>06</month><year>2015</year></pub-date><volume>06</volume><issue>06</issue><fpage>411</fpage><lpage>422</lpage><history><date date-type="received"><day>18</day>	<month>January</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>23</month>	<year>June</year>	</date><date date-type="accepted"><day>26</day>	<month>June</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   Background: Pituitary insufficiencies after traumatic brain injury (TBI) and subarachnoid haem-orrhage (SAH) have been reported with very varying frequencies. The aim of this study was to describe the pituitary function in the acute phase after TBI and SAH in a cohort of adults and relate the results to injury variables. Methods: Adults admitted to the neurointensive care unit in our hospital after moderate and severe TBI or SAH were included prospectively. Demographic, clinical, laboratory, including ACTH stimulation test, and radiological data were collected. Results: A total of 130 adults, 84 (19 women/65 men) with TBI and 46 (38 women/8 men) with SAH were included. Nine patients with TBI and six patients with SAH responded insufficiently to ACTH stimulation; 14 patients with TBI and 9 patients with SAH had low fT4 and low-normal TSH levels. No relations were seen between hormonal levels and injury variables. Conclusions: Pituitary deficiencies occur after TBI and SAH, and a continuous endocrine evaluation of these patients is important. Our study could not define a marker for increased risk for pituitary deficiency. The long-term clinical outcome of the pathological hormone levels in the early phase after TBI and SAH is not known in detail and further studies to elucidate this are needed. 
  
 
</p></abstract><kwd-group><kwd>Hormone Disturbance</kwd><kwd> Pituitary</kwd><kwd> Traumatic Brain Injury</kwd><kwd> Subarachnoidal Haemorrhage</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Traumatic Brain Injury (TBI) and Subarachnoid Hemorrhage (SAH) with reported annual incidence rates of 235 - 506 [<xref ref-type="bibr" rid="scirp.57461-ref1">1</xref>] and 2 - 22 cases per 100,000 inhabitants [<xref ref-type="bibr" rid="scirp.57461-ref2">2</xref>] respectively are major causes of disability and death. Early prediction of long-term outcome is based on a complex interplay between multiple factors including the primary injury and subsequent initiated injury cascade [<xref ref-type="bibr" rid="scirp.57461-ref3">3</xref>] , occurrence of secondary insults [<xref ref-type="bibr" rid="scirp.57461-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.57461-ref5">5</xref>] , and acute as well as later neurorehabilitation interventions [<xref ref-type="bibr" rid="scirp.57461-ref6">6</xref>] . Recently, the occurrence and potential impact of pituitary dysfunction has gained increasing interest [<xref ref-type="bibr" rid="scirp.57461-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.57461-ref8">8</xref>] . Several studies have demonstrated pituitary dysfunction after TBI and SAH but questions remain about the frequency and impact of such dysfunction both in the acute and chronic phase after these events.</p><p>Hypopituitarism following TBI [<xref ref-type="bibr" rid="scirp.57461-ref9">9</xref>] -[<xref ref-type="bibr" rid="scirp.57461-ref16">16</xref>] may be isolated, multiple or even total. The prevalence of post-trau- matic hypopituitarism (PTHP) varies significantly among studies and ranges from 2% to 90% [<xref ref-type="bibr" rid="scirp.57461-ref9">9</xref>] -[<xref ref-type="bibr" rid="scirp.57461-ref17">17</xref>] . Several factors may affect the prevalence of PTHP including the time interval between TBI and investigation of pituitary function, the severity of the injury and the diagnostic tests [<xref ref-type="bibr" rid="scirp.57461-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.57461-ref17">17</xref>] .</p><p>Only few studies have reported on hypopituitarism in the acute phase following TBI, such as gonadotropin, adrenal, growth hormone (GH) and thyroidal deficiency [<xref ref-type="bibr" rid="scirp.57461-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.57461-ref11">11</xref>] . The studies on hypopituitarism following SAH, such as gonadotropin, adrenocorticotrophic (ACTH), GH insufficiency and thyroidal deficiency are also scarce [<xref ref-type="bibr" rid="scirp.57461-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.57461-ref18">18</xref>] -[<xref ref-type="bibr" rid="scirp.57461-ref22">22</xref>] .</p><p>In the acute phase multiple factors in addition to the primary injury and the ubiquitous stress response to critical illness may play a role in the development of pituitary deficiencies [<xref ref-type="bibr" rid="scirp.57461-ref23">23</xref>] . For example, the relation between pituitary dysfunction and secondary insults has to be considered. Following TBI and SAH secondary insults [<xref ref-type="bibr" rid="scirp.57461-ref24">24</xref>] , such as systemic hypotension, hypoxemia, pyrexia, increasing intracranial pressure (ICP), occur and have been shown to be associated with poor outcome in TBI patients [<xref ref-type="bibr" rid="scirp.57461-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.57461-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.57461-ref26">26</xref>] but not in SAH patients [<xref ref-type="bibr" rid="scirp.57461-ref5">5</xref>] . Little is known about the potential impact of such secondary insults on pituitary function and vice versa.</p><p>Here we report data on pituitary function in patients with a moderate to severe TBI or an aneurysmal SAH during the initial neurointensive care with regard to the frequency and type of pituitary dysfunction and the relationship to injury variables. We hypothesized that pituitary dysfunction is related to the severity of the primary injury and secondary insults.</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>We performed a prospective, observational study of patients with moderate or severe traumatic brain injury or subarachnoid haemorrhage. Eligible were patients admitted to the Neurointensive care unit (NICU) at Karolinska University Hospital from March 1, 2009 until June 30, 2012 for TBI or SAH. Patients were included in the NICU and followed up at the Department of Rehabilitation Medicine at Danderyd University Hospital, Stockholm Sweden. Inclusion was not performed during holidays for logistic and administrative reasons. Inclusion required a moderate or severe TBI or SAH due to a ruptured aneurysm, a lowest GCS score during the first day after the event of 3 - 13, age ≥ 18 years, living in the Stockholm region and informed consent. For patients, who were unconscious or otherwise unable to give inform consent, the closest relative was asked. Patients with anticipated fatal outcome were not included. The study was approved by Regional Ethical Review Board in Stockholm (No: 2008/3:9 2008/1574-31/3).</p><sec id="s2_1"><title>2.1. Data Collection</title><p>Demographic data (age, sexand smoking status), clinical and radiological parameters were prospectively collected from the NICU medical records and transferred to the study data base.</p><sec id="s2_1_1"><title>2.1.1. Severity Grading</title><p>In addition to the GCS score, clinical severity grading of patients with SAH severity was by the Hunt-Hess scale (HH): 1) asymptomatic or minimal headache, nuchal rigidity; 2) moderate to severe headache, no neurological deficit except for cranial nerve palsy; 3) drowsiness, confusion, mild focal deficit; 4) stupor, moderate to severe hemiparesis, early decerebrate; 5) deep coma, decerebrate posturing, moribund appearance. Aneurysms were verified by computed tomography angiography (CTAI) or digital subtraction angiography (DSA). Aneurysms were divided into aneurysm from the anterior cerebral circulation and the posterior cerebral circulation.</p><p>Computed tomography (CT) lesion [<xref ref-type="bibr" rid="scirp.57461-ref27">27</xref>] grading of TBI was according to the CRASH model [<xref ref-type="bibr" rid="scirp.57461-ref28">28</xref>] : presence of one or more petechial haemorrhages (cerebral contusions), obliteration of the third ventricle or basal cisterns, subarachnoid bleed, midline shift &gt; 5 mm , and non-evacuated haematoma (subdural/epidural). Brain oedema, basilar skull fractures and facial fracture were added to the CT model.</p><p>CT lesion grading of SAH was according to Fisher scale (1: no blood detected; 2: SAH less than 1 mm thick; 3: SAH more than 1 mm thick; and 4: intraventricular or parenchymal blood with or without diffuse SAH) [<xref ref-type="bibr" rid="scirp.57461-ref27">27</xref>] .</p></sec><sec id="s2_1_2"><title>2.1.2. Assessment of Endocrine Function</title><p>ACTH stimulation test (Synacthene test) and analyses of thyroid function (S-fT4, S-TSH and S-fT3) were performed 10 days post injury or at discharge from NICU, if earlier. The lowest and highest S-osmolality and P-sodium values during this time period were also recorded.</p><p>Measurements of S-cortisol, S-fT4, S-fT3, S-TSH, P-Na and S-osmolality were performed at the Department of Clinical Chemistry in Karolinska University Hospital using routine commercial kits and reference data were provided by the department.</p><p>ACTH stimulation test was performed by administration of Synacthene (250 &#181;g) intravenously and blood samples were drawn before and after 30 minutes for S-cortisol analysis.A normal response to the Synacthene test was defined as S-cortisol at 30 minutes &gt;550 nmol/l. The patients were divided in three subgroups according to the cortisol response to the Synacthene test; one group with a subnormal response, one group with a cortisol response between 550 and 1000 nmol/l and one group with a cortisol response &gt;1000 nmol/l.</p><p>Thyroidal dysfunction was defined as fT4 level below the normal reference range concomitantly with normal or low TSH. Reference value for S-TSH: 0.4 - 3.5 mE/l (DxI) and S-fT4: 8 - 14 pmol/l (DxI).</p><p>Reference values for others analysis were; S-fT3: 3.5 - 5.4 nmol/l (Dxl); P-Na: 137 - 145 mmol/l; and S-osm- olality 280 - 300 mosmol/kg.</p><p>Measurements of gonadotropins, sex-steroids and growth hormone were not included in the evaluation.</p></sec><sec id="s2_1_3"><title>2.1.3. Assessment of Injury Variables and Secondary Insults</title><p>All patients were monitored online using a computerized surveillance system, ICU-pilot (&#181;dialysis, Stockholm, Sweden). Secondary insults were defined according to the Edinburgh University Secondary Insult Grades (EUSIG) [<xref ref-type="bibr" rid="scirp.57461-ref26">26</xref>] . Intracranial pressure (ICP) &gt; 20 mm Hg, mean arterial blood pressure (MAP) &lt; 70 mm Hg and temperature &gt;38˚C with a duration exceeding 5 minutes were considered secondary insults.Secondary insults were defined as a deviation from the reference interval lasting for at least 5 minutes. The insults were graded as mild, moderate or severe (<xref ref-type="table" rid="table1">Table 1</xref>).</p></sec></sec><sec id="s2_2"><title>2.2. Statistics</title><p>Statistical analysis was performed using IBM SPSS Statistics version 22 (IBM Corporation, Armonk, New York, USA).</p><p>This is an observational study reporting on frequencies as mean &#177; SD [range (min-max)] or number (percent) or median (percentile) or median (min-max).</p><p>Nonparametric methods were used as data were not normally distributed. The Mann-Whitney U test was used for group comparisons of GCS, Hunt and Hess grade, Fisher grade and peak S-100B (12 - 36 h). The Fisher’s exact test was used for comparisons of CT-scan findings, pupil size at admission, pupil reaction to light stimulation at admission. The Kruskal-Wallis test was used for multiple comparisons of ICP, pyrexia, MAP level and hormones. In all cases, significance level was set at p &lt; 0.05.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Demographical Data and Injury Characteristics</title><p>A total of 130 patients were included, 84 with TBI and 46 with SAH patients. Two of the included TBI patients</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Secondary insults at the NICU</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Mild</th><th align="center" valign="middle" >Moderate</th><th align="center" valign="middle" >Severe</th></tr></thead><tr><td align="center" valign="middle" >Intracranial hypertension ICP (mmHg)</td><td align="center" valign="middle" >20 - 30</td><td align="center" valign="middle" >30 - 40</td><td align="center" valign="middle" >&gt;40</td></tr><tr><td align="center" valign="middle" >Hypotension MAP (mmHg)</td><td align="center" valign="middle" >55 - 70</td><td align="center" valign="middle" >40 - 55</td><td align="center" valign="middle" >&lt;40</td></tr><tr><td align="center" valign="middle" >Pyrexia ˚C</td><td align="center" valign="middle" >38 - 39</td><td align="center" valign="middle" >39 - 40</td><td align="center" valign="middle" >&gt;40</td></tr></tbody></table></table-wrap><p>were 16 years.</p><p>Of patients with TBI, 19 were women and 65 men, mean age was 48.3 &#177; 16.9 years, 63 patients had a severe brain injury and 21 patients a moderate brain injury according to the admission GCS score (mean GCS score 6.6 &#177; 3.1). Main causes of TBI were falls and traffic accidents. Most common traumatic CT scan pathology were cerebral contusions (n = 65), subarachnoidal blood (n = 64) and subdural/epidural haematoma (n = 72). Data are displayed in <xref ref-type="table" rid="table2">Table 2</xref>.</p><p>Of 46 patients with SAH, 38 were women and 8 men, mean age was 58.3 &#177; 10.5 years, 31 patients had severe and 15 patients a moderate brain injury according to the admission GCS score (mean GCS score 4.4 &#177; 3.9). Most frequent Hunt &amp; Hess scores at admission were 3 and 4. SAH was confirmed by CT scan in all (Fisher grade 2 - 4). Aneurysm location was 34 patients the anterior cerebral circulation (AACC) in 34, the posterior cerebral circulation (APCC) in 9, both anterior and posterior cerebral circulation (AAPCC) in 2, while the aneurysm could not be located in one patient. Data are displayed in <xref ref-type="table" rid="table3">Table 3</xref>.</p></sec><sec id="s3_2"><title>3.2. Endocrine Evaluations</title><p>The endocrine evaluations were performed at day 10 - 15 after TBI or SAH. However, in 25 TBI and 17 SAH patients this was performed day 11 - 15 post injuries. Data were collected between 6.00 and 10.00 am in 49 patents with TBI and 20 patients with SAH, and between 10.00 am and 6.00 pm for the others.</p><p>Results from the Synacthene test were available for 77 patients with TBI and for 43 patients with SAH as shown in <xref ref-type="table" rid="table4">Table 4</xref>. Nine patients (12%) with TBI and 6 patients (14%) with SAH (6 AACC) responded with</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Baseline data of patients with traumatic brain injury (TBI) (n = 84)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >(mean &#177; S.D.) (min - max)</th></tr></thead><tr><td align="center" valign="middle" >Age, years</td><td align="center" valign="middle" >48.3 &#177; 16.9 (16 - 79)</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >25.5 &#177; 4.9 (16.5 - 42.2)</td></tr><tr><td align="center" valign="middle" >GCS</td><td align="center" valign="middle" >6.6 &#177; 3.1 (3 - 13)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >n (%)</td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >65 (77%)</td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >19 (23%)</td></tr><tr><td align="center" valign="middle" >Smokers</td><td align="center" valign="middle" >26 (34%)</td></tr><tr><td align="center" valign="middle" >GCS</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Moderate (9 - 13)</td><td align="center" valign="middle" >21 (25%)</td></tr><tr><td align="center" valign="middle" >Severe (3 - 8)</td><td align="center" valign="middle" >63 (75%)</td></tr><tr><td align="center" valign="middle" >Trauma cause</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Traffic accident</td><td align="center" valign="middle" >29 (35%)</td></tr><tr><td align="center" valign="middle" >Fall</td><td align="center" valign="middle" >47 (56%)</td></tr><tr><td align="center" valign="middle" >Violence in</td><td align="center" valign="middle" >5 (6%)</td></tr><tr><td align="center" valign="middle" >Other</td><td align="center" valign="middle" >3 (4%)</td></tr><tr><td align="center" valign="middle" >CT scan</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cerebral contusions</td><td align="center" valign="middle" >65 (77%)</td></tr><tr><td align="center" valign="middle" >Obliteration of the third ventricle or basal cisterns</td><td align="center" valign="middle" >24 (29%)</td></tr><tr><td align="center" valign="middle" >Subarachnoid bleed</td><td align="center" valign="middle" >64 (76%)</td></tr><tr><td align="center" valign="middle" >Midline shift &gt; 5 mm</td><td align="center" valign="middle" >31 (37%)</td></tr><tr><td align="center" valign="middle" >Subdural/epidural haematoma</td><td align="center" valign="middle" >72 (86%)</td></tr><tr><td align="center" valign="middle" >Brain oedema</td><td align="center" valign="middle" >16 (19%)</td></tr><tr><td align="center" valign="middle" >Basilar skull fractures</td><td align="center" valign="middle" >41(49%)</td></tr><tr><td align="center" valign="middle" >Facial fracture</td><td align="center" valign="middle" >27 (32%)</td></tr></tbody></table></table-wrap><p>BMI, Body Mass Index (kg/m<sup>2</sup>); CT, Computed Tomography; GCS, Glasgow Coma Scale.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Baseline data of patients with subarachnoid haemorrhage (SAH) (n = 46)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >(mean &#177; S.D.) (min - max)</th></tr></thead><tr><td align="center" valign="middle" >Age, years</td><td align="center" valign="middle" >58.3 &#177; 10.5 (28 - 82)</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >25.5 &#177; 4.5 (16.0 - 36.5)</td></tr><tr><td align="center" valign="middle" >GCS</td><td align="center" valign="middle" >7.4 &#177; 3.9 (3 - 13)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >n (%)</td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >38 (83%)</td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >8 (17%)</td></tr><tr><td align="center" valign="middle" >Smokers</td><td align="center" valign="middle" >23 (51%)</td></tr><tr><td align="center" valign="middle" >GCS</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Moderate (9 - 13)</td><td align="center" valign="middle" >15 (33%)</td></tr><tr><td align="center" valign="middle" >Severe (3 - 8)</td><td align="center" valign="middle" >31 (67%)</td></tr><tr><td align="center" valign="middle" >Hunter &amp; Hess grade</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1 (2%)</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3 (6%)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >16 (35%)</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >21 (46%)</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >5 (11%)</td></tr><tr><td align="center" valign="middle" >Fisher grade</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3 (6%)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >10 (22%)</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >33 (72%)</td></tr><tr><td align="center" valign="middle" >Aneurysm localisation</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Anterior cerebral circulation AACA</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Anterior communicating artery ACoA</td><td align="center" valign="middle" >16 (35%)</td></tr><tr><td align="center" valign="middle" >Middle cerebral artery MCA</td><td align="center" valign="middle" >14 (30%)</td></tr><tr><td align="center" valign="middle" >Anterior choroidal artery AChA</td><td align="center" valign="middle" >2 (4%)</td></tr><tr><td align="center" valign="middle" >Internal carotid artery ICA</td><td align="center" valign="middle" >3 (7%)</td></tr><tr><td align="center" valign="middle" >Pericallosal artery</td><td align="center" valign="middle" >1 (2%)</td></tr><tr><td align="center" valign="middle" >Posterior cerebral circulation APCC</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Posterior communicating artery PCoA</td><td align="center" valign="middle" >5 (11%)</td></tr><tr><td align="center" valign="middle" >Basilar artery</td><td align="center" valign="middle" >2 (4%)</td></tr><tr><td align="center" valign="middle" >Vertebral artery</td><td align="center" valign="middle" >2 (4%)</td></tr><tr><td align="center" valign="middle" >Posterior inferior cerebellar artery PICA</td><td align="center" valign="middle" >2 (4%)</td></tr></tbody></table></table-wrap><p>subnormal increase in S-cortisol, of whom, 7 patients with TBI and all 6 patients with SAH had been treated with different types of steroids (betamethasone, hydrocortisone, methylprednisolone).</p><p>In 27 patients (32%) with TBI and 23 patients (50%) with SAH (14 AACC, 7 APCC, and 1 AAPCC) the cortisol response was exaggerated and ranged 1000 - 2000 nmol/l or above (one patient with TBI had an exaggerated response of 3300 nmol/l). Of patients with exaggerated response, 6 patients with TBI and 3 patients with</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Clinical characteristics of TBI and SAH patients in three subgroups of adrenal response</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ><sup> </sup></th><th align="center" valign="middle"  colspan="2"  >Cortisol dysfunction</th><th align="center" valign="middle"  colspan="2"  >Exaggerated adrenal response</th></tr></thead><tr><td align="center" valign="middle" >TBI (n = 9)</td><td align="center" valign="middle" >SAH (n = 6)</td><td align="center" valign="middle" >TBI (n = 27)</td><td align="center" valign="middle" >SAH (n = 23)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >mean &#177; S.D</td><td align="center" valign="middle" >mean &#177; S.D.</td><td align="center" valign="middle" >mean &#177; S.D.</td><td align="center" valign="middle" >mean &#177; S.D.</td></tr><tr><td align="center" valign="middle" >Cortisol nmol/l</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >0 min (6 - 10 am)<sup>a</sup></td><td align="center" valign="middle" >161 &#177; 85**</td><td align="center" valign="middle" >63 &#177; 54**</td><td align="center" valign="middle" >727 &#177; 124***</td><td align="center" valign="middle" >720 &#177; 237**</td></tr><tr><td align="center" valign="middle" >0 min (10 am - 6 pm)<sup>b</sup></td><td align="center" valign="middle" >17 &#177; 0</td><td align="center" valign="middle" >116 &#177; 88</td><td align="center" valign="middle" >721 &#177; 330**</td><td align="center" valign="middle" >665 &#177; 168**</td></tr><tr><td align="center" valign="middle" >30 min<sup>c</sup></td><td align="center" valign="middle" >471 &#177; 61***</td><td align="center" valign="middle" >396 &#177; 116***</td><td align="center" valign="middle" >1208 &#177; 425***</td><td align="center" valign="middle" >1248 &#177; 214***</td></tr><tr><td align="center" valign="middle" >GCS</td><td align="center" valign="middle" >7.33 &#177; 1.9</td><td align="center" valign="middle" >7.33 &#177; 4.6</td><td align="center" valign="middle" >5.96 &#177; 2.8</td><td align="center" valign="middle" >7.43 &#177; 4.1</td></tr><tr><td align="center" valign="middle" >Peak S100B (12 - 36 h) &#181;g/l</td><td align="center" valign="middle" >0.61 &#177; 0.7</td><td align="center" valign="middle" >0.36 &#177; 0.2</td><td align="center" valign="middle" >0.58 &#177; 0.9</td><td align="center" valign="middle" >0.83 &#177; 3.0*</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >median</td><td align="center" valign="middle" >median</td><td align="center" valign="middle" >median</td><td align="center" valign="middle" >median</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >(min - max)</td><td align="center" valign="middle" >(min - max)</td><td align="center" valign="middle" >(min - max)</td><td align="center" valign="middle" >(min - max)</td></tr><tr><td align="center" valign="middle" >GCS</td><td align="center" valign="middle" >7 (4 - 11)</td><td align="center" valign="middle" >6 (3 - 13)</td><td align="center" valign="middle" >5 (3 - 13)</td><td align="center" valign="middle" >6 (3 - 13)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >n (%)</td><td align="center" valign="middle" >n (%)</td><td align="center" valign="middle" >n (%)</td><td align="center" valign="middle" >n (%)</td></tr><tr><td align="center" valign="middle" >Hunt &amp; Hess</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2 (9)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3 (50)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >7 (30)</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2 (33)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >12 (52)</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1 (17)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2 (9)</td></tr><tr><td align="center" valign="middle" >Fisher grade</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2 (9)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5 (22)</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >6 (100)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >16 (69)</td></tr><tr><td align="center" valign="middle" >DT scan</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cerebral contusions</td><td align="center" valign="middle" >6 (67)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >20 (74)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Obliteration of the third ventricle or basal cisterns</td><td align="center" valign="middle" >3 (33)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >10 (37)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Subarachnoid bleed</td><td align="center" valign="middle" >8 (89)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >20 (74)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Midline shift &gt; 5 mm</td><td align="center" valign="middle" >1 (11)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >12 (44)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Subdural/epidural haematoma</td><td align="center" valign="middle" >8 (89)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >24 (89)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Brain oedema</td><td align="center" valign="middle" >4 (44)*</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >7 (26)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Basilar skull fractures</td><td align="center" valign="middle" >4 (44)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >14 (52)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Facial fracture</td><td align="center" valign="middle" >2 (22)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >8 (30)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p><sup>a</sup>Cortisol 6.00 - 10.00 am; <sup>b</sup>Cortisol 10.00 am - 6.00 pm; <sup>c</sup>Cortisol response to ACTH. ***p &lt; 0.001, **p &lt; 0.01, *p &lt; 0.05.</p><p>SAH had been treated with different types of steroids (betamethazone, hydrocortisone, metylprednisolone). The cortisol responses (mean values &#177; 1 S.D.) to Synacthen in three subgroups are presented in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p><p>In the TBI group with an exaggerated cortisol response to Synacthene test, the admission GCS score was non-significantly lower than in TBI patients with a normal or insufficient response as well as compared with SAH patients from all groups. In for the SAH group with insufficient response to Synachtene, the GCS score was non-significantly lower than in SAH patients with a normal or an exaggerated response as well as compared with TBI patients from all groups.</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Cortisol response (mean values &#177; 1 S.D.) to ACTH stimula- tion in three subgroups, 10 days after TBI and SAH. Dashed lines illustrate range of normal variation</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/8-2101049x6.png"/></fig><p>There were no differences in the response to Synacthen with or without CT scan pathology except for brain oedema, which was more frequent in SAH patients with a subnormal responses (p = 0.026).</p><p>There were no differences between S-cortisol response in patients with SAH or TBI with regard to Fisher grade, Hunter &amp; Hess grade, pupil size or light reaction. However, a higher peak of S100B (12 - 36 h) [<xref ref-type="bibr" rid="scirp.57461-ref29">29</xref>] was noticed in SAH patients with an exaggerated response (p = 0.043). Data are displayed in <xref ref-type="table" rid="table4">Table 4</xref>.</p><p>Data on thyroid hormones and TSH were available from all patients. Low levels of s-fT4 were found in 18 (22%) patients with TBI and in 10 (22%) patients with SAH. Levels of S-TSH were within the normal range in the majority of patients with TBI (13/18) and SAH (6/10). Low levels of S-TSH were found in one patient with TBI and 3 patients with SAH.</p><p>In 14 (17%) patients with TBI and in 9 (20%) patients with SAH (AACC), a combination of low T4 and low TSH or normal TSH was observed. This was related to the presence of subarachnoid blood on CT scan in TBI patients (p = 0.027) but not to GCS score, pupil size, pupil reaction, peak S100B (12 - 36 h), Hunter &amp; Hess grade or Fisher grade in neither group. Data are displayed in <xref ref-type="table" rid="table5">Table 5</xref>.</p><p>High levels of S-fT4 were noted in 8 (10%) patients with TBI and in 7 (16%) patients with SAH (5 AACC, 1 APCC, and 1 AAPCC).We found differences between high level of s-fT4 and peak S100B (12 - 36 h) in SAH patients (p = 0.004). Neither were there any differences between high level of s-fT4 and subarachnoid blood (p = 0.044) or facial fracture in TBI patients (p = 0.043) or between high fT4 and GCS score, pupil size, pupil reaction, Hunter &amp; Hess grade and Fisher grade. Data are displayed in <xref ref-type="table" rid="table5">Table 5</xref>.</p><p>Low S-fT3 was seen in 26 (32%) patients with TBI and 19 (42%) patients with SAH (16 AACC, 2 APCC, and 1 AAPCC). Patients with TBI and low fT3 had lower GCS scores (p = 0.029) while no differences were observed between high fT4 and pupil size, pupil reaction, peak S100B (12 - 36 h), DT scan pathology, Hunter &amp; Hess grade or Fisher grade. Data are displayed in <xref ref-type="table" rid="table5">Table 5</xref>.</p><p>Among TBI patients with a subnormal response to Synacthene test, 5/9 had also low T4 and normal or low TSH and among SAH patients with a sub-normal response to Synacthene test 3/6 had also low T4 and normal or low TSH.</p><p>Among TBI patients with an exaggerated cortisol response at the Synacthene test, 1/27 had also low T4 and normal or low TSH and among SAH with an exaggerated cortisol response to the Synacthene test 3/23 had also low T4 and normal or low TSH.</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Clinical characteristics of TBI and SAH patients in three subgroups of adrenal response</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ><sup> </sup></th><th align="center" valign="middle"  colspan="2"  >Thyroidal dysfunction</th><th align="center" valign="middle"  colspan="2"  >High fT4</th><th align="center" valign="middle"  colspan="2"  >Low fT3</th></tr></thead><tr><td align="center" valign="middle" >TBI (n = 14)</td><td align="center" valign="middle" >SAH (n = 9)</td><td align="center" valign="middle" >TBI (n = 8)</td><td align="center" valign="middle" >SAH (n = 7)</td><td align="center" valign="middle" >TBI (n = 26)</td><td align="center" valign="middle" >SAH (n = 19)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >mean &#177; S.D</td><td align="center" valign="middle" >mean &#177; S.D</td><td align="center" valign="middle" >mean &#177; S.D.</td><td align="center" valign="middle" >mean &#177; S.D.</td><td align="center" valign="middle" >mean &#177; S.D</td><td align="center" valign="middle" >mean &#177; S.D</td></tr><tr><td align="center" valign="middle" >TSH mE/l (DxI)</td><td align="center" valign="middle" >1.5 &#177; 1.0</td><td align="center" valign="middle" >1.1 &#177; 1.0</td><td align="center" valign="middle" >1.6 &#177; 0.4</td><td align="center" valign="middle" >1.8 &#177; 1.1</td><td align="center" valign="middle" >1.7 &#177; 1.3</td><td align="center" valign="middle" >2.1 &#177; 3.9</td></tr><tr><td align="center" valign="middle" >fT4 pmol/l (DxI)</td><td align="center" valign="middle" >6.4 &#177; 0.8***</td><td align="center" valign="middle" >6.7 &#177; 0.5***</td><td align="center" valign="middle" >15.2 &#177; 0.5***</td><td align="center" valign="middle" >16.1 &#177; 1.3***</td><td align="center" valign="middle" >8.4 &#177; 2.5**</td><td align="center" valign="middle" >8.7 &#177; 2.7**</td></tr><tr><td align="center" valign="middle" >fT3 nmol/l (Dxl)</td><td align="center" valign="middle" >3.3 &#177; 0.9**</td><td align="center" valign="middle" >3.2 &#177; 1.0**</td><td align="center" valign="middle" >4.2 &#177; 0.6</td><td align="center" valign="middle" >3.9 &#177; 0.6</td><td align="center" valign="middle" >2.9 &#177; 0.7***</td><td align="center" valign="middle" >3.0 &#177; 0.2***</td></tr><tr><td align="center" valign="middle" >GCS</td><td align="center" valign="middle" >7.7 &#177; 2.6</td><td align="center" valign="middle" >6.1 &#177; 3.4</td><td align="center" valign="middle" >7.1 &#177; 3.2</td><td align="center" valign="middle" >9.3 &#177; 4.2</td><td align="center" valign="middle" >7.5 &#177; 3.2*</td><td align="center" valign="middle" >6.5 &#177; 3.4</td></tr><tr><td align="center" valign="middle" >Peak S100B (12 - 36 h) &#181;g/l</td><td align="center" valign="middle" >0.54 &#177; 0.6</td><td align="center" valign="middle" >0.20 &#177; 0.1</td><td align="center" valign="middle" >0.86 &#177; 1.0</td><td align="center" valign="middle" >2.9 &#177; 5.7**</td><td align="center" valign="middle" >0.51 &#177; 0.5</td><td align="center" valign="middle" >0.17 &#177; 0.1</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >median (min - max)</td><td align="center" valign="middle" >median (min - max)</td><td align="center" valign="middle" >median (min - max)</td><td align="center" valign="middle" >median (min - max)</td><td align="center" valign="middle" >median (min - max)</td><td align="center" valign="middle" >median (min - max)</td></tr><tr><td align="center" valign="middle" >GCS</td><td align="center" valign="middle" >7 (4 - 13)</td><td align="center" valign="middle" >5 (3 - 13)</td><td align="center" valign="middle" >6.5 (3 - 13)</td><td align="center" valign="middle" >11 (3 - 13)</td><td align="center" valign="middle" >7 (3 - 13)*</td><td align="center" valign="middle" >6 (3 - 13)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >n (%)</td><td align="center" valign="middle" >n (%)</td><td align="center" valign="middle" >n (%)</td><td align="center" valign="middle" >n (%)</td><td align="center" valign="middle" >n (%)</td><td align="center" valign="middle" >n (%)</td></tr><tr><td align="center" valign="middle" >Hunt&amp; Hess</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0(0)</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1 (14)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2 (10)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3 (33)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4 (57)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >6 (32)</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4 (45)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2 (29)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >8 (42)</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2 (22)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3 (16)</td></tr><tr><td align="center" valign="middle" >Fisher grade</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1 (5)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1 (11)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1 (14)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4 (21)</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >8 (89)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >6 (86)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >14 (74)</td></tr><tr><td align="center" valign="middle" >DT scan</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cerebral contusions</td><td align="center" valign="middle" >10 (71)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >6 (75)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >19 (73)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Obliteration of the third ventricle or basal cisterns</td><td align="center" valign="middle" >4 (29)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4 (50)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >8 (31)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Subarachnoid bleed</td><td align="center" valign="middle" >14 (100)*</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3 (38)*</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >20 (77)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Midline shift &gt; 5 mm</td><td align="center" valign="middle" >6 (43)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4 (50)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >10 (38)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Subdural/epidural haematoma</td><td align="center" valign="middle" >14 (100)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >7 (88)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >22 (85)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Brain oedema</td><td align="center" valign="middle" >5 (36)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2 (25)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4 (15)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Basilar skull fractures</td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3 (38)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >14 (54)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Facial fracture</td><td align="center" valign="middle" >3 (21)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0 (0)*</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5 (19)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>***p &lt; 0.001, ** p &lt; 0.01, *p &lt; 0.05.</p><p>Sixty-three (75%) of patients with TBI and 40 (90%) of patients with SAH had P-Na &gt;146 and S-osmolality</p><p>&gt;300 mosm/kg. Of these 9 TBI and 9 SAH patients had been treated with fludrocortisone, and 7 patients with TBI and 10 with SAH had been treated with desmopressin.</p><p>No differences between high plasma levels of sodium and S-osmolality, and GCS, pupil size, pupil reaction, peak S100B (12 - 36 h), changes on DT scan, Fisher grade, and Hunter &amp; Hess grade were found.</p><p>In 10 (12%) patients with TBI and in 2 (4%) patients with SAH a low P-Na in combination with a low S-osmolality was observed. Both patients with SAH lost in weight (−6.1 to −1.4 kg) while 6 patients with TBI lost weight (−7.3 to −1.1 kg) and 4 increased in weight (+1.5 to + 7.1 kg ).</p><p>The number of patients was too few to draw any statistical conclusions.</p>Secondary Insults<p>The total monitored time possible for analyses of ICP was 243 &#177; 183 hours for TBI patients and 349 &#177; 204 hours for SAH patients. For two patients with TBI monitoring with ICU pilot system could not be done.</p><p>Out of 82 TBI patients, 68 patients experienced intracranial hypertension (mild [20 - 29 mmHg, n = 13]; moderate [30 - 39 mmHg, n = 23] and severe [&gt;40 mmHg; n = 32]). In SAH group of 46 patients, 44 patients experiences intracranial hypertension (mild [20 - 29 mmHg, n=4]; moderate [30 - 39 mmHg, n = 16] and severe [&gt;40 mmHg; n = 24]). In patients with TBI, S-fT4 was higher in those with intracranial hypertension when compared with those without intracranial hypertension (p = 0.045) while no other differences of pituitary hormones between these groups were observed.</p><p>Out of 84 TBI patients, 75 patients experienced pyrexia (mild [38˚C - 39˚C; n = 34]; moderate [39˚C - 40˚C, n = 38] and severe [&gt;40˚C; n = 3]). In SAH group of 46 patients, 44 patients experiences pyrexia (mild, [38˚C - 39˚C, n = 21]; moderate [39˚C - 40˚C; n = 20] and severe [&gt;40˚C; n = 3]). No differences of pituitary hormones between these groups were observed.</p><p>Out of 84 TBI patients, 82 patients experienced low mean arterial blood pressure (MAP) (mild [&lt;70 mmHg; n = 6]; moderate [&lt;55 mmHg, n = 24] and severe [&lt;40 mmHg; n = 52]). All 46 patients with SAH experiences low mean arterial blood pressure (MAP (mild [&lt;70 mmHg; n = 2]; moderate [&lt;55 mmHg, n = 10] and severe [&lt;40 mmHg; n = 34]). No differences of pituitary hormones between these groups were observed.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>The study demonstrates that perturbations in the levels of cortisol and thyroid hormones were frequent in the acute phase after TBI and SAH, adrenal and thyroidal functions are often disturbed in the acute phase after TBI and SAH, the most conspicuous findings being the exaggerated response to Synacthene and low thyroid hormones. Additionally, 12% - 14% of the patients had a subnormal response to the Synacthene test, and 17% - 22% had low circulating thyroid hormones. A specific marker predicting affection of the pituitary function could not be defined, and a clear relation to the severity of the trauma was neither seen.</p><p>The reported affection in the acute phase of cerebral trauma on pituitary function has varied in different studies. In 50 patients with moderate to severe brain injury, Agha et al. [<xref ref-type="bibr" rid="scirp.57461-ref10">10</xref>] observed in the acute phase an occurrence of pituitary deficiencies, i.e. adrenal insufficiency (16%), and thyroidal deficiency (2%). In the study by Klose et al. [<xref ref-type="bibr" rid="scirp.57461-ref11">11</xref>] pituitary deficiencies with hypothyroidism and hypocortisolism were found in 33 and 4% of 46 patients during the acute phase after mild to severe TBI. Prasanna et al. [<xref ref-type="bibr" rid="scirp.57461-ref16">16</xref>] observed low levels of GH in 49 %, TSH in 45%, fT4 in 47 %, cortisol in 2 % patients one week after moderate to severe TBI.</p><p>Regarding SAH, Tanriverdi et al. [<xref ref-type="bibr" rid="scirp.57461-ref15">15</xref>] in 22 patients with SAH observed in the acute phase 23% deficient on adrenocorticotrophic (ACTH). Furthermore Parenti et al. [<xref ref-type="bibr" rid="scirp.57461-ref19">19</xref>] reported the frequency of pituitary deficiencies in 60 patients during the acute phase after mild to severe SAH and found 7% ACTH deficiency. Recently Kronvall et al. [<xref ref-type="bibr" rid="scirp.57461-ref20">20</xref>] observed in 51 patients with SAH in acute stage, ACTH deficiency in 8% and thyrotrophic dysfunction in 6%.</p><p>In the present study we found that 12% of patients with TBI and 14% of patients with SAH had a sub-normal response to Synacthene test and 17% and 20%, respectively low T4 and normal or low TSH. Several explanations for the observed differences in prevalence of pituitary deficiencies may be considered. One could be the use of different criteria for the diagnosis of hormone deficiencies in addition to use of different tests. In this study the ACTH deficiency was defined when cortisol response to Synacthene was &lt;550 nmol/lat 30 minutes. In Klose et al. [<xref ref-type="bibr" rid="scirp.57461-ref11">11</xref>] adrenal insufficiency was defined as 30 min cortisol &lt;500 nmol/l in response to both the ITT (insulin tolerance test) and the Synacthene test. In Tanriverdi et al. [<xref ref-type="bibr" rid="scirp.57461-ref18">18</xref>] ACTH deficiency was indicated when basal cortisol was below 193 nmol/l.</p><p>Regarding thyroidal deficiency Agha et al. [<xref ref-type="bibr" rid="scirp.57461-ref10">10</xref>] defined thyroidal deficiency as fT4 level below the normal reference range with low TSH. Other factors potentially influencing on the hormone levels are the physiological reaction to the stress caused by the trauma and the use of glucocorticoids. Probably, a multitude of combinations of all these factors can occur and explain the different frequencies of pituitary dysfunction reported. Interestingly, in this study a majority of patients had the physiologically expected exaggerated response to Synacthene and low levels of circulating thyroid hormones. Anyhow, all studies including our have shown that some patients develop pituitary deficiencies, and therefore the pituitary function in these patients should be evaluated. The impact on clinical long-term outcome of the pathological hormone levels in the early phase after TBI and SAH are not known in detail and more studies are warranted.</p><p>There are no previous published studies on the relation between secondary insults and pituitary function but theoretically severe or moderate secondary insults would be assumed to impair pituitary function. Despite that a majority of the patients had severe intracranial hypertension, this was associated only with fT4 levels in patients with TBI, which may reflect a physiological reaction to injury severity. Notably, secondary insults were continuously monitored and treated and short duration of secondary insults may have prevented more prominent impact on pituitary function.</p>Study Limitations<p>Patients with TBI and SAH are heterogeneous and many other factors, such as infection, raised intracranial pressure, seizures, vasospasm, arterial hypotension, hypoxemia, pyrexia can potentially affect the hormone levels and the development of secondary injuries. Larger cohorts are needed to control for such other factors.</p></sec><sec id="s5"><title>5. Conclusion</title><p>In conclusion, this study confirmed that pituitary deficiencies occur in a substantial number of patients early after TBI and SAH, and thus that it is important to evaluate these patients continuously with endocrine examinations. Our study could not define a single marker for increased risk for pituitary deficiency. The long-term clinical impact on outcome of the pathological hormone levels in the early phase after TBI and SAH is not know in detail and further studies to elucidate this are needed.</p></sec><sec id="s6"><title>Competing Interests</title><p>The authors have no competing interests to declare.</p></sec><sec id="s7"><title>Authors’ Contributions</title><p>All authors participated in planning the study, data collection, data analyses and writing.</p></sec><sec id="s8"><title>Acknowledgements</title><p>The study was partly funded by a research grant from Pfizer, Sweden. Anna T&#246;lli has received supportby grants from Stockholm County Council (ALF-grants).</p></sec><sec id="s9"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.57461-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Tagliaferri, F., et al. (2006) A Systematic Review of Brain Injury Epidemiology in Europe. Acta Neurochirurgica (Wien), 148, 255-268. http://dx.doi.org/10.1007/s00701-005-0651-y</mixed-citation></ref><ref id="scirp.57461-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ingall, T., et al. (2000) A Multinational Comparison of Subarachnoid Hemorrhage Epidemiology in the WHO MONICA Stroke Study. Stroke, 31, 1054-1061. http://dx.doi.org/10.1161/01.STR.31.5.1054</mixed-citation></ref><ref id="scirp.57461-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Gaetz, M. (2004) The Neurophysiology of Brain Injury. Clinical Neurophysiology, 115, 4-18.http://dx.doi.org/10.1016/S1388-2457(03)00258-X</mixed-citation></ref><ref id="scirp.57461-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">McHugh, G.S., et al. (2007) Prognostic Value of Secondary Insults in Traumatic Brain Injury: Results from the IMPACT Study. Journal of Neurotrauma, 24, 287-293. http://dx.doi.org/10.1089/neu.2006.0031</mixed-citation></ref><ref id="scirp.57461-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ryttlefors, M., et al. (2007) Secondary Insults in Subarachnoid Hemorrhage: Occurrence and Impact on Outcome and Clinical Deterioration. Neurosurgery, 61, 704-714. http://dx.doi.org/10.1227/01.NEU.0000298898.38979.E3</mixed-citation></ref><ref id="scirp.57461-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Turner-Stokes, L. (2008) Evidence for the Effectiveness of Multi-Disciplinary Rehabilitation Following Acquired Brain Injury: A Synthesis of Two Systematic Approaches. Journal of Rehabilitation Medicine, 40, 691-701.http://dx.doi.org/10.1227/01.NEU.0000298898.38979.E3</mixed-citation></ref><ref id="scirp.57461-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Hannon, M.J., Sherlock, M. and Thompson, C.J. (2011) Pituitary Dysfunction Following Traumatic Brain Injury or Subarachnoid Haemorrhage—In “Endocrine Management in the Intensive Care Unit”. Best Practice. Research Clinical Endocrinology. Metabolism, 25, 783-798. http://dx.doi.org/10.1016/j.beem.2011.06.001</mixed-citation></ref><ref id="scirp.57461-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kokshoorn, N.E., et al. (2010) Hypopituitarism Following Traumatic Brain Injury: Prevalence Is Affected by the Use of Different Dynamic Tests and Different Normal Values. European Journal of Endocrinology, 162, 11-18.http://dx.doi.org/10.1530/EJE-09-0601</mixed-citation></ref><ref id="scirp.57461-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kelly, D.F., et al. (2000) Hypopituitarism Following Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage: A Preliminary Report. Journal of Neurosurgery, 93,743-752. http://dx.doi.org/10.3171/jns.2000.93.5.0743</mixed-citation></ref><ref id="scirp.57461-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Agha, A., et al. (2004) Neuroendocrine Dysfunction in the Acute Phase of Traumatic Brain Injury. Clinical Endocrinology (Oxford), 60, 584-591. http://dx.doi.org/10.1111/j.1365-2265.2004.02023.x</mixed-citation></ref><ref id="scirp.57461-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Klose, M., Juul, A., Struck, J., Morgenthaler, N.G., Kosteljanetz, M. and Feldt-Rasmussen, U. (2007) Acute and Long-Term Pituitary Insufficiency in Traumatic Brain Injury: A Prospective Single-Centre Study. Clinical Endocrinology, 67, 598-606. http://dx.doi.org/10.1111/j.1365-2265.2007.02931.x</mixed-citation></ref><ref id="scirp.57461-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Schneider, H.J., Schneider, M., Saller, B., Petersenn, S., Uhr, M., Husemann, B., et al. (2006) Prevalence of Anterior Pituitary Insufficiency 3 and 12 Months after Traumatic Brain Injury. European Journal of Endocrinology, 154, 259-265. http://dx.doi.org/10.1530/eje.1.02071</mixed-citation></ref><ref id="scirp.57461-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kokshoorn, N.E., Smit, J.W., Nieuwlaat, W.A., Tiemensma, J., Bisschop, P.H., Groote Veldman, R., et al. (2011) Low Prevalence of Hypopituitarism after Traumatic Brain Injury: A Multicenter Study. European Journal of Endocrinology, 165, 225-231. http://dx.doi.org/10.1530/EJE-11-0365</mixed-citation></ref><ref id="scirp.57461-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Berg, C., Oeffner, A., Schumm-Draeger, P.M., Badorrek, F., Brabant, G., Gerbert, B., et al. (2010) Prevalence of Anterior Pituitary Dysfunction in Patients Following Traumatic Brain Injury in a German Multi-Centre Screening Program. Experimental and Clinical Endocrinology Diabetes, 118, 139-144. http://dx.doi.org/10.1055/s-0029-1225611</mixed-citation></ref><ref id="scirp.57461-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kopczak, A., Kilimann, I., von Rosen, F., Krewer, C., Schneider, H.J., Stalla, G.K. and Schneider, M. (2014) Screening for Hypopituitarism in 509 Patients with Traumatic Brain Injury or Subarachnoid Hemorrhage. Journal of Neurotrauma, 31, 99-107. http://dx.doi.org/10.1089/neu.2013.3002</mixed-citation></ref><ref id="scirp.57461-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Prasanna, K.L., Mittal, R.S. and Gandhi, A. (2015) Neuroendocrine Dysfunction in Acute Phase of Moderate-to-Severe Traumatic Brain Injury: A Prospective Study. Brain Injury, 29, 336-342.http://dx.doi.org/10.3109/02699052.2014.955882</mixed-citation></ref><ref id="scirp.57461-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Klose, M., Stochholm, K., Janukonyté, J., Lehman Christensen, L., Frystyk, J., Andersen, M., et al. (2014) Prevalence of Posttraumatic Growth Hormone Deficiency Is Highly Dependent on the Diagnostic Set-Up: Results from the Danish National Study on Posttraumatic Hypopituitarism. The Journal of Clinical Endocrinology Metabolism, 99, 101-110.http://dx.doi.org/10.1210/jc.2013-2397</mixed-citation></ref><ref id="scirp.57461-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Tanriverdi, F., Dagli, A.T., Karaca, Z., Unluhizarci, K., Selcuklu, A., Casanueva, F.F. and Kelestimur, F. (2007) High Risk of Pituitary Dysfunction Due to Aneurysmal Subarachnoid Haemorrhage: A Prospective Investigation of Anterior Pituitary Function in the Acute Phase and 12 Months after the Event. Clinical Endocrinology, 67, 931-937.http://dx.doi.org/10.1111/j.1365-2265.2007.02989.x</mixed-citation></ref><ref id="scirp.57461-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Parenti, G., Cecchi, P.C., Ragghianti, B., Schwarz, A., Ammannati, F., Mennonna, P., et al. (2011) Evaluation of the Anterior Pituitary Function in the Acute Phase after Spontaneous Subarachnoid Hemorrhage. Journal of Endocrinological Investigation, 34, 361-365. http://dx.doi.org/10.1007/BF03347460</mixed-citation></ref><ref id="scirp.57461-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Kronvall, E., Valdemarsson, S., Saveland, H. and Nilsson, O.G. (2014) Pituitary Dysfunction after Aneurysmal Subarachnoid Hemorrhage Is Associated with Impaired Early Outcome. World Neurosurgery, 81, 529-537.http://dx.doi.org/10.1016/j.wneu.2013.10.038</mixed-citation></ref><ref id="scirp.57461-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Pereira, J.L., Albuquerque, L.A., Dellaretti, M., Carvalho, G.T., Vieira Jr., G., Brochado, V.M., et al. (2013) Pituitary Deficiency after Aneurysmal Subarachnoid Hemorrhage. Clinics, 68, 745-749.http://dx.doi.org/10.6061/clinics/2013(06)04</mixed-citation></ref><ref id="scirp.57461-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kronvall, E., Valdemarsson, S., Saveland, H. and Nilsson, O.G. (2015) High Prevalence of Pituitary Dysfunction after Aneurysmal Subarachnoid Hemorrhage: A Long-Term Prospective Study Using Dynamic Endocrine Testing. World Neurosurgery, 83, 574-582.</mixed-citation></ref><ref id="scirp.57461-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Ligtenberg, J.J., Girbes, A.R., Beentjes, J.A., Tulleken, J.E., van der Werf, T.S. and Zijlstra, J.G. (2001) Hormones in the Critically Ill Patient: To Intervene or Not to Intervene? Intensive Care Medicine, 27, 1567-1577.http://dx.doi.org/10.1007/s001340101050</mixed-citation></ref><ref id="scirp.57461-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Miller, J.D. and Becker, D.P. (1982) Secondary Insults to the Injured Brain. The Royal College of Surgeons of Edinburgh, 27, 292-298.</mixed-citation></ref><ref id="scirp.57461-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Chesnut, R.M., Marshall, L.F., Klauber, M.R., Blunt, B.A., Baldwin, N., Eisenberg, H.M., et al. (1993) The Role of Secondary Brain Injury in Determining Outcome from Severe Head Injury. The Journal of Trauma, 34, 216-222.http://dx.doi.org/10.1097/00005373-199302000-00006</mixed-citation></ref><ref id="scirp.57461-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Jones, P.A., Andrews, P.J., Midgley, S., Anderson, S.I., Piper, I.R., Tocher, J.L., et al. (1994) Measuring the Burden of Secondary Insults in Head-Injured Patients during Intensive Care. Journal of Neurosurgical Anesthesiology, 6, 4-14.http://dx.doi.org/10.1097/00008506-199401000-00001</mixed-citation></ref><ref id="scirp.57461-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Fisher, C.M., Kistler, J.P. and Davis, J.M. (1980) Relation of Cerebral Vasospasm to Subarachnoid Hemorrhage Visualized by Computerized Tomographic Scanning. Neurosurgery, 6, 1-9.http://dx.doi.org/10.1227/00006123-198001000-00001</mixed-citation></ref><ref id="scirp.57461-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Edwards, P., Farrell, B., Lomas, G., Mashru, R., Ritchie, N., Roberts, I., et al. (2002) The MRC CRASH Trial: Study Design, Baseline Data, and Outcome in 1000 Randomised Patients in the Pilot Phase. Emergency Medicine Journal, 19, 510-514. http://dx.doi.org/10.1136/emj.19.6.510</mixed-citation></ref><ref id="scirp.57461-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Thelin, E.P., Johannesson, L., Nelson, D. and Bellander, B.M. (2013) S100B Is an Important Outcome Predictor in Traumatic Brain Injury. Journal of Neurotrauma, 30, 519-528. http://dx.doi.org/10.1089/neu.2012.2553</mixed-citation></ref></ref-list></back></article>